We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




CRISPR-TB Blood Test to Enable Early Disease Diagnosis and Public Screening

By LabMedica International staff writers
Posted on 22 Jan 2025

Tuberculosis (TB) continues to be a leading cause of global mortality, with 10. More...

6 million new cases and 1.6 million deaths annually. Diagnosing TB remains difficult, with smear microscopy offering only moderate sensitivity and specificity, and culture methods having slow sample-to-answer times. Though newer tests like Elispot, Elisa Blood assays, and PCR assays have shown promise, they have not significantly impacted global TB detection due to their limitations. Now, a breakthrough has been made with the first qualitative real-time polymerase chain reaction (PCR) assay that integrates Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology to detect Mycobacterium tuberculosis (Mtb) cell-free DNA (cfDNA) in human serum and EDTA plasma.

IntelliGenome (Houston, TX, USA) has developed the first molecular diagnostic platform capable of detecting low-abundance target nucleic acids in blood. This platform enables precise detection of disease-specific cell-free DNA (cfDNA), making it ideal for early diagnosis and mass screening. The CRISPR-TB Blood test by IntelliGenome provides a rapid, accurate, and cost-effective way to diagnose both pulmonary tuberculosis (PTB) and extra-pulmonary tuberculosis (EPTB) in all patient groups. The test identifies species-specific TB cfDNA sequences directly from blood samples, eliminating the need for sputum collection, which is especially beneficial for vulnerable populations such as children, elderly patients, and the critically ill. IntelliGenome’s CRISPR-TB Blood Test has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

"The FDA's Breakthrough Device Designation for our CRISPR-TB Blood Test is a significant milestone for IntelliGenome," said Wilson Zhang MD MSc, CEO of IntelliGenome. “This recognition highlights our commitment to advancing innovative, accessible solutions for tuberculosis diagnosis and improving patient outcomes.”

Related Links:
IntelliGenome


New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automatic Hematology Analyzer
DH-800 Series
New
Automated Biochemical Analyzer
iBC 900
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Platelets sequester cfDNA during circulation (Murphy L. et al., Science, 2025; DOI: 10.1126/science.adp3971)

Platelets Could Improve Early and Minimally Invasive Detection of Cancer

Platelets are widely recognized for their role in blood clotting and scab formation, but they also play a crucial role in immune defense by detecting pathogens and recruiting immune cells.... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Pathology

view channel
image: Researchers Marco Gustav (right) and MD Nic G. Reitsam (left) discuss the study data (Photo courtesy of Anja Stübner/EKFZ)

AI Model Simultaneously Detects Multiple Genetic Colorectal Cancer Markers in Tissue Samples

Colorectal cancer is a complex disease influenced by multiple genetic alterations. Traditionally, studies and diagnostic tools have focused on predicting only one mutation at a time, overlooking the interplay... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.